- Why in news
- On 2 July 2026 the Health Ministry announced an amendment to the Drugs Rules, 1945. It brings cell and stem cell-derived products, gene therapeutics and xenografts under the Central License Approving Authority (CLAA) framework.
- What it is
- The Drugs Rules, 1945 are made under the Drugs and Cosmetics Act, 1940 and govern the manufacture, sale and licensing of drugs in India. Under the CLAA framework, certain critical drugs and biological products are licensed with joint oversight of Central and State regulators, so that standards stay uniform across States.
- Parent law
- The Drugs Rules, 1945 are framed under the Drugs and Cosmetics Act, 1940, which sets the regulatory structure for drugs and cosmetics.
- Existing CLAA categories
- Vaccines, large volume parenterals (IV solutions above 100 ml) and r-DNA based medicines were already under joint Central and State supervision.
- New categories added
- The amendment adds cell or stem cell-derived products, gene therapeutic products and xenografts to the CLAA list.
- Xenografts
- Xenografts are animal tissue-derived products, such as heart valves, that can be transplanted into humans. They are used in cardiology and orthopedics.
- Joint oversight
- Central and State Licensing Authorities will jointly oversee these products, aiming at uniform regulatory standards across the country.
- Central regulator
- The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India, is the central drug regulator.
Don’t confuse with Drugs and Cosmetics Act, 1940 vs Drugs Rules, 1945: The Act is the parent law passed by Parliament. The Rules are subordinate legislation made under it, and they are what this amendment changes.
Don’t confuse with Gene therapy vs xenograft: Gene therapy alters or replaces genes to treat disease. A xenograft is animal-derived tissue transplanted into humans.
Laws, judgments and statutory bodies: 30 Prelims questions since 2013 (what the law says, who chairs, legal basis). In Mains, 44 news-triggered questions, most in GS2, asking for provisions and challenges.
Why it matters
- Complex, fast-changing therapies such as CAR-T and gene editing get stronger safety scrutiny.
- Uniform standards across States reduce regulatory gaps and support faster, safer adoption of new technology.
Problems
- Regulators need specialised scientific expertise and capacity at both Central and State levels.
- Joint oversight may cause delays or coordination problems, and high costs may limit patient access.
Way forward
- Build technical capacity in State regulators through training and shared protocols with CDSCO.
- Set clear timelines and guidance so that safety checks do not slow innovation.
Put in your answer
CLAA expansion: Cell therapies, gene therapeutics and xenografts now come under joint Central-State licensing, which can be cited as an example of regulation keeping pace with science.
- 2014Mains GS3 · Q11Can antibiotic overuse and lack of prescription cause resistance; monitoring mechanisms
- 2017Mains GS3 · Q6Describe stem cell therapy and its advantages over other treatments
- 2024Mains GS4 · Q12Ethical dilemma of expediting drug trials under pressure during a viral outbreak
- 2015Prelims Q23Which nanotechnology statements are correct: targeted drug delivery and gene therapy contribution
- 2012Prelims Q16Which statements on stem cells are correct: mammal-derived, drug screening, medical therapies
- 2021Prelims Q66Which statements on mitochondrial diseases and replacement therapy are correct
UPSC’s own questions that come close to this issue, from our Prelims and Mains banks.
No practice question for this one; the card may still help an answer. Why: Amendment widens joint central-state oversight to CAR-T, stem cell, gene therapy and xenografts. Lasting regulatory topic; laws were 23 of 327 Prelims questions, but few firm facts here.
Worth revising until Prelims 2028: most news questions come within two years of the event.